Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Systematic Reviews
Published in: Systematic Reviews 1/2024

Open Access 01-12-2024 | Levothyroxine | Research

Cardiovascular and bone health outcomes in older people with subclinical hypothyroidism treated with levothyroxine: a systematic review and meta-analysis

Authors: Mia Holley, Salman Razvi, Mohammed Saif Farooq, Rosie Dew, Ian Maxwell, Scott Wilkes

Published in: Systematic Reviews | Issue 1/2024

Login to get access

Abstract

Background

Thyroid dysfunction is common in older people, with females at higher risk. Evidence suggests that thyroid-stimulating hormone (TSH) levels naturally increase with age. However, as uniform serum TSH reference ranges are applied across the adult lifespan, subclinical hypothyroidism (SCH) diagnosis is more likely in older people, with some individuals also being commenced treatment with levothyroxine (LT4). It is unclear whether LT4 treatment in older people with SCH is associated with adverse cardiovascular or bone health outcomes.

Methods

A systematic review and meta-analysis were performed to synthesise previous studies evaluating cardiovascular and bone health outcomes in older people with SCH, comparing LT4 treatment with no treatment. PubMed, Embase, Cochrane Library, MEDLINE, and Web of Science databases were searched from inception until March 13, 2023, and studies that evaluated cardiovascular and bone health events in people with SCH over 50 years old were selected.

Results

Six articles that recruited 3853 participants were found, ranging from 185 to 1642 participants, with the proportion of females ranging from 45 to 80%. The paucity of data resulted in analysis for those aged over 65 years only. Additionally, a study with 12,212 participants aged 18 years and older was identified; however, only data relevant to patients aged 65 years and older were considered for inclusion in the systematic review. Of these 7 studies, 4 assessed cardiovascular outcomes, 1 assessed bone health outcomes, and 2 assessed both. A meta-analysis of cardiovascular outcomes revealed a pooled hazard ratio of 0.89 (95% CI 0.71–1.12), indicating no significant difference in cardiovascular risk between older individuals with SCH treated with LT4 compared to those without treatment. Due to overlapping sub-studies, meta-analysis for bone health outcomes was not possible.

Conclusions

This systematic review and meta-analysis found no significant association between LT4 use and cardiovascular and bone health outcomes in SCH participants over 65 years.

Systematic review registration

PROSPERO CRD42022308006
Appendix
Available only for authorised users
Literature
1.
2.
3.
4.
Rodondi N, Newman AB, Vittinghoff E, de Rekeneire N, Satterfield S, Harris TB, et al. Subclinical hypothyroidism and the risk of heart failure, other cardiovascular events, and death. Arch Intern Med. 2005;165(21):2460–6.PubMedCrossRef
5.
Hyland KA, Arnold AM, Lee JS, Cappola AR. Persistent subclinical hypothyroidism and cardiovascular risk in the elderly: the cardiovascular health study. J Clin Endocrinol Metab. 2013;98(2):533–40.PubMedCrossRef
6.
de Jongh RT, Lips P, van Schoor NM, Rijs KJ, Deeg DJH, Comijs HC, et al. Endogenous subclinical thyroid disorders, physical and cognitive function, depression, and mortality in older individuals. Eur J Endocrinol. 2011;165(4):545–54.PubMedCrossRef
7.
Boekholdt SM, Titan SM, Wiersinga WM, Chatterjee K, Basart DCG, Luben R, et al. Initial thyroid status and cardiovascular risk factors: the EPIC-Norfolk prospective population study. Clin Endocrinol (Oxf). 2010;72(3):404–10.PubMedCrossRef
8.
Waring AC, Harrison S, Samuels MH, Ensrud KE, LeBLanc ES, Hoffman AR, et al. Thyroid function and mortality in older men: a prospective study. J Clin Endocrinol Metab. 2012;97(3):862–70.PubMedPubMedCentralCrossRef
9.
Cappola AR, Fried LP, Arnold AM, Danese MD, Kuller LH, Burke GL, et al. Thyroid status, cardiovascular risk, and mortality in older adults. JAMA. 2006;295(9):1033–41.PubMedPubMedCentralCrossRef
10.
Gammage MD, Parle JV, Holder RL, Roberts LM, Hobbs FDR, Wilson S, et al. Association between serum free thyroxine concentration and atrial fibrillation. Arch Intern Med. 2007;167(9):928–34.PubMedCrossRef
11.
Abrahamsen B, Jørgensen HL, Laulund AS, Nybo M, Bauer DC, Brix TH, et al. The excess risk of major osteoporotic fractures in hypothyroidism is driven by cumulative hyperthyroid as opposed to hypothyroid time: an observational register-based time-resolved cohort analysis. J Bone Miner Res. 2015;30(5):898–905.PubMedCrossRef
12.
Gonzalez Rodriguez E, Stuber M, Del Giovane C, Feller M, Collet TH, Löwe AL, et al. Skeletal effects of levothyroxine for subclinical hypothyroidism in older adults: a TRUST randomized trial nested study. J Clin Endocrinol Metab. 2020;105(1):dgz058.PubMedCrossRef
13.
Meier C, Beat M, Guglielmetti M, Christ-Crain M, Staub J, Kraenzlin M. Restoration of euthyroidism accelerates bone turnover in patients with subclinical hypothyroidism: a randomized controlled trial. Osteoporos Int. 2004;15(3):209–16.PubMedCrossRef
14.
15.
Okosieme O, Gilbert J, Abraham P, Boelaert K, Dayan C, Gurnell M, et al. Management of primary hypothyroidism: statement by the British Thyroid Association Executive Committee. Clin Endocrinol (Oxf). 2016;84(6):799–808.PubMedCrossRef
16.
17.
Razvi S, Korevaar TIM, Taylor P. Trends, determinants, and associations of treated hypothyroidism in the United Kingdom, 2005–2014. Thyroid. 2019;29(2):174–82.PubMedCrossRef
18.
Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab. 2002;87(2):489–99.PubMedCrossRef
19.
Vadiveloo T, Donnan PT, Murphy MJ, Leese GP. Age- and gender-specific TSH reference intervals in people with no obvious thyroid disease in Tayside, Scotland: the Thyroid Epidemiology, Audit, and Research Study (TEARS). J Clin Endocrinol Metab. 2013;98(3):1147–53.PubMedCrossRef
20.
21.
22.
Eligar V, Taylor P, Okosieme O, Leese G, Dayan C. Thyroxine replacement: a clinical endocrinologist’s viewpoint. Ann Clin Biochem. 2016;53(4):421–33.PubMedCrossRef
23.
24.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;29(372):n71.CrossRef
25.
Sterne JAC, Egger M, Moher D, Boutron I (editors). Chapter 10: Addressing reporting biases. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.​training.​cochrane.​org/​handbook.
26.
Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;18(343):d5928.CrossRef
27.
28.
Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328(7454):1490.PubMedCrossRef
29.
Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64(4):401–6.PubMedCrossRef
30.
31.
32.
Nygaard Andersen M, Schjerning-Olsen, Clausager Madsen J, Faber J, Torp-Pedersen C, Gislason G, et al. Major adverse cardiac events (MACE) and all-cause mortality in levothyroxine substituted individuals with subclinical hypothyroidism: a large cohort study. Eur Heart J. 2014;35:903.
33.
Razvi S, Ingoe L, Keeka G, Oates C, McMillan C, Weaver JU. The beneficial effect of L-thyroxine on cardiovascular risk factors, endothelial function, and quality of life in subclinical hypothyroidism: randomized, crossover trial. J Clin Endocrinol Metab. 2007;92(5):1715–23.PubMedCrossRef
34.
Razvi S, Weaver JU, Vanderpump MP, Pearce SHS. The incidence of ischemic heart disease and mortality in people with subclinical hypothyroidism: reanalysis of the Whickham Survey cohort. J Clin Endocrinol Metab. 2010;95(4):1734–40.PubMedCrossRef
35.
Alotaibe HF, Alolaiwi LA, Almutairi A, Alsubaie N, Badri M, Balaha MF, et al. Association between levothyroxine replacement therapy and osteoporosis in Riyadh, Saudi Arabia: a matched case-control study. Pharmazie. 2022;77(10):295–8.PubMed
36.
Huang HK, Wang JH, Kao SL. Association of hypothyroidism with all-cause mortality: a cohort study in an older adult population. J Clin Endocrinol Metab. 2018;103(9):3310–8.PubMedCrossRef
37.
Lillevang-Johansen M, Abrahamsen B, Jørgensen HL, Brix TH, Hegedüs L. Duration of over- and under-treatment of hypothyroidism is associated with increased cardiovascular risk. Eur J Endocrinol. 2019;180(6):407–16.PubMedCrossRef
38.
Vestergaard P, Rejnmark L, Mosekilde L. Influence of hyper- and hypothyroidism, and the effects of treatment with antithyroid drugs and levothyroxine on fracture risk. Calcif Tissue Int. 2005;77(3):139–44.PubMedCrossRef
39.
Viniol A, Hickstein L, Walker J, Donner-Banzhoff N, Baum E, Becker A. Influence of thyroid hormone therapy on the fracture rate - a claims data cohort study. Bone. 2016;86:86–90.PubMedCrossRef
40.
Lillevang-Johansen M, Abrahamsen B, Jørgensen HL, Brix TH, Hegedüs L. Over- and under-treatment of hypothyroidism is associated with excess mortality: a register-based cohort study. Thyroid. 2018;28(5):566–74.PubMedCrossRef
41.
Abbey EJ, McGready J, Ferrucci L, Simonsick EM, Mammen JSR. Thyroid hormone supplementation and all-cause mortality in community-dwelling older adults: results from the Baltimore Longitudinal Study of Aging. J Am Geriatr Soc. 2021;69(5):1283–90.PubMedPubMedCentralCrossRef
42.
Thayakaran R, Adderley NJ, Sainsbury C, Torlinska B, Boelaert K, Šumilo D, et al. Thyroid replacement therapy, thyroid stimulating hormone concentrations, and long term health outcomes in patients with hypothyroidism: longitudinal study. BMJ. 2019;3(366):l4892.CrossRef
43.
Waring AC, Harrison S, Fink HA, Samuels MH, Cawthon PM, Zmuda JM, et al. A prospective study of thyroid function, bone loss, and fractures in older men: the MrOS study. J Bone Miner Res. 2013;28(3):472–9.PubMedCrossRef
44.
Inoue K, Ritz B, Brent GA, Ebrahimi R, Rhee CM, Leung AM. Association of subclinical hypothyroidism and cardiovascular disease with mortality. JAMA Netw Open. 2020;3(2):e1920745.PubMedCrossRef
45.
Pearce SHS, Razvi S, Yadegarfar ME, Martin-Ruiz C, Kingston A, Collerton J, et al. Serum thyroid function, mortality and disability in advanced old age: the Newcastle 85+ Study. J Clin Endocrinol Metab. 2016;101(11):4385–94.PubMedPubMedCentralCrossRef
46.
Giri A, Edwards TL, LeGrys VA, Lorenz CE, Funk MJ, Schectman R, et al. Subclinical hypothyroidism and risk for incident ischemic stroke among postmenopausal women. Thyroid. 2014;24(8):1210–7.PubMedPubMedCentralCrossRef
47.
Hak AE, Pols HA, Visser TJ, Drexhage HA, Hofman A, Witteman JC. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study. Ann Intern Med. 2000;132(4):270–8.PubMedCrossRef
48.
Tseng FY, Lin WY, Lin CC, Lee LT, Li TC, Sung PK, et al. Subclinical hypothyroidism is associated with increased risk for all-cause and cardiovascular mortality in adults. J Am Coll Cardiol. 2012;60(8):730–7.PubMedCrossRef
49.
Silva N, Santos O, Morais F, Gottlieb I, Hadlich M, Rothstein T, et al. Subclinical hypothyroidism represents an additional risk factor for coronary artery calcification, especially in subjects with intermediate and high cardiovascular risk scores. Eur J Endocrinol. 2014;171(3):327–34.PubMedCrossRef
50.
Walsh JP, Bremner AP, Bulsara MK, O’Leary P, Leedman PJ, Feddema P, et al. Subclinical thyroid dysfunction as a risk factor for cardiovascular disease. Arch Intern Med. 2005;165(21):2467–72.PubMedCrossRef
51.
Chaker L, van den Berg ME, Niemeijer MN, Franco OH, Dehghan A, Hofman A, et al. Thyroid function and sudden cardiac death: a prospective population-based cohort study. Circulation. 2016;134(10):713–22.PubMedCrossRef
52.
Bano A, Chaker L, Mattace-Raso FUS, van der Lugt A, Ikram MA, Franco OH, et al. Thyroid function and the risk of atherosclerotic cardiovascular morbidity and mortality: the Rotterdam Study. Circ Res. 2017;121(12):1392–400.PubMedCrossRef
53.
Martin SS, Daya N, Lutsey PL, Matsushita K, Fretz A, McEvoy JW, et al. Thyroid function, cardiovascular risk factors, and incident atherosclerotic cardiovascular disease: the Atherosclerosis Risk in Communities (ARIC) Study. J Clin Endocrinol Metab. 2017;102(9):3306–15.PubMedPubMedCentralCrossRef
54.
Ceresini G, Ceda GP, Lauretani F, Maggio M, Usberti E, Marina M, et al. Thyroid status and 6-year mortality in elderly people living in a mildly iodine-deficient area: the aging in the Chianti Area Study. J Am Geriatr Soc. 2013;61(6):868–74.PubMedPubMedCentralCrossRef
55.
Maraka S, Owen R, Ospina NS, Knox M, Dodds T, Spencer H, Dishongh K, Albashaireh A, Shah A, Syed S, Naqvi S, Motahari H, Thumma S, Ambrogini E, Brito J. Discontinuation of low-dose levothyroxine therapy for patients with subclinical hypothyroidism is feasible and safe: interim analysis of a pilot, randomized, double-blind, placebo-controlled trial. Thyroid. 2022;32:A49.
56.
Grossman A, Feldhamer I, Meyerovitch J. Treatment with levothyroxin in subclinical hypothyroidism is associated with increased mortality in the elderly. Eur J Intern Med. 2018;50:65–8.PubMedCrossRef
57.
Wouters HJCM, Slagter SN, Muller Kobold AC, van der Klauw MM, Wolffenbuttel BHR. Epidemiology of thyroid disorders in the Lifelines Cohort Study (the Netherlands). PLoS ONE. 2020;15(11):e0242795.PubMedPubMedCentralCrossRef
58.
Andersen MN, Olsen AMS, Madsen JC, Faber J, Torp-Pedersen C, Gislason GH, et al. Levothyroxine substitution in patients with subclinical hypothyroidism and the risk of myocardial infarction and mortality. PLoS ONE. 2015;10(6):e0129793.PubMedPubMedCentralCrossRef
59.
Zijlstra L, Jukema J, Westendorp R, Du Puy R, Poortvliet R, Kearney P, et al. Levothyroxine treatment and cardiovascular outcomes in older people with subclinical hypothyroidism: pooled individual results of two randomised controlled trials. Front Endocrinol. 2021;12:674841.CrossRef
60.
Razvi S, Weaver JU, Butler TJ, Pearce SHS. Levothyroxine treatment of subclinical hypothyroidism, fatal and nonfatal cardiovascular events, and mortality. Arch Intern Med. 2012;172(10):811–7.PubMedCrossRef
61.
Gencer B, Moutzouri E, Blum MR, Feller M, Collet TH, Delgiovane C, et al. The impact of levothyroxine on cardiac function in older adults with mild subclinical hypothyroidism: a randomized clinical trial. Am J Med. 2020;133(7):848–856.e5.PubMedCrossRef
62.
Stott D, Rodondi N, Kearney P, Ford I, Westendorp R, Mooijaart S, et al. Thyroid hormone therapy for older adults with subclinical hypothyroidism. N Engl J Med. 2017;376(26):2534–44.PubMedCrossRef
63.
Mooijaart SP, Du Puy RS, Stott DJ, Kearney PM, Rodondi N, Westendorp RGJ, et al. Association between levothyroxine treatment and thyroid-related symptoms among adults aged 80 years and older with subclinical hypothyroidism. JAMA. 2019;322(20):1977–86.PubMedPubMedCentralCrossRef
64.
65.
Metadata
Title
Cardiovascular and bone health outcomes in older people with subclinical hypothyroidism treated with levothyroxine: a systematic review and meta-analysis
Authors
Mia Holley
Salman Razvi
Mohammed Saif Farooq
Rosie Dew
Ian Maxwell
Scott Wilkes
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Systematic Reviews / Issue 1/2024
Electronic ISSN: 2046-4053
DOI
https://doi.org/10.1186/s13643-024-02548-7

Other articles of this Issue 1/2024

Systematic Reviews 1/2024 Go to the issue

Protocol

Indigenous approaches to health assessment: a scoping review protocol

Research

Effectiveness of gold nanoparticles in prevention and treatment of oral mucositis in animal models: a systematic review

Research

Searching for the social determinants of health: observations from evidence synthesis publications

Protocol

Mechanisms behind gender transformative approaches targeting adolescent pregnancy in low- and middle-income countries: a realist synthesis protocol

Systematic review update

Global prevalence of sexual dysfunction in cardiovascular patients: a systematic review and meta-analysis

Research

Reported outcomes in patients with iron deficiency or iron deficiency anemia undergoing major surgery: a systematic review of outcomes